A Phase 3 interventional study of Eylea (Aflibercept, BAY86-5321) and Laser photocoagulation in Retinopathy of Prematurity (ROP), sponsored by Bayer. Completed at 90 sites in 27 countries. Open to participants aged Up to 32 Weeks. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.
169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.
This study's enrollment of 113 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.
Browse Retinopathy of Prematurity studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with treatment-naïve ROP classified according to the International Classification for ROP in at least one eye as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
Drug: Eylea (Aflibercept, BAY86-5321)
Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
Procedure: Laser photocoagulation
Solution in a sterile glass vial, Dose A, IVT injection.
Transpupillary conventional laser ablative therapy
Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes
Active ROP was defined as ROP requiring treatment. Unfavorable structural outcomes included retinal detachment, macular dragging, macular fold, or retrolental opacity.
Time frame: At 24 weeks after starting study treatment
Proportion of Participants Requiring Intervention With a Second Treatment Modality
A second treatment modality for ROP was either rescue treatment or any other surgical or nonsurgical treatment for ROP (e.g. IVT anti-VEGF injection, ablative laser therapy, cryotherapy, or vitrectomy) captured as concomitant medication or surgery after study start.
Time frame: From baseline (treatment) up to week 24.
Proportion of Participants With Recurrence of ROP
Participants with recurrence of ROP were defined as subjects requiring re-treatment or rescue treatment after in the past the absence of treatment-requiring active ROP had been confirmed by the investigator.
Time frame: From baseline (treatment) up to week 24.
Exploration of ROP Activity Scale Proposed by the International Neonatal Consortium
Eyes were evaluated for change in ROP activity scale proposed by the International Neonatal Consortium (2018). ROP Activity Scale value range is from 0 to 22. Value 0 to 7 are considered mild, 8 to 12 are moderate, and 13 to 22 are severe. Value 0 means the best and value 22 means the worst. Eyes evaluation was done at baseline and each visit.
Time frame: From baseline (treatment) up to week 24.
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular TEAEs in treated eyes only were reported
Time frame: From baseline (treatment) up to week 24
Percentage of Participants With Ocular Serious Adverse Events (SAEs)
Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular SAEs in treated eyes only were reported.
Time frame: From baseline (treatment) up to week 24
Percentage of Participants With Systemic TEAEs
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic TEAEs only were reported.
Time frame: From baseline (treatment) up to week 24
Percentage of Participants With Systemic SAEs
Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic SAEs only were reported.
Time frame: From baseline (treatment) up to week 24
Concentrations of Free Aflibercept in Plasma
Blood samples for determination of aflibercept concentrations in plasma were collected in the aflibercept 0.4 mg arm at Day 1 (within 24 hours after injection), and at weeks 2 and 4, and if feasible also at weeks 8, 12 and 24. Statistics for week 8, 12, 24 not calculated as \> 1/3 of the concentrations were below the lower limit of quantification. Free Aflibercept Concentrations in Plasma were only measured in the Aflibercept 0.4 mg treatment arm.
Time frame: From Day 1 up to week 24.
Number of Participants With Anti-drug Antibodies (ADA)
Immunogenicity was characterized by anti-drug antibody (ADA) responses in patients in the aflibercept 0.4 mg arm. Serum samples were taken at baseline prior to the injection and at 12 weeks after injection. ADA titers were summarized for 3 categories: Low (titer \<1,000); Moderate (1,000 ≤ titer ≤ 10,000); High (titer \>10,000). ADA in serum were only measured in the Aflibercept 0.4 mg treatment arm.
Time frame: Baseline (treatment) and 12 weeks after aflibercept injection
Number of Participants With Potential Neutralizing Antibodies (NAb)
NAb status was evaluated for the samples that were positive in the ADA assay and had sufficient volume to analyze. NAb were only measured in participants with positive ADA in the Aflibercept 0.4 mg treatment arm
Time frame: At 12 weeks after aflibercept injection
Number of Aflibercept Administrations
Total number of injections in both eyes.
Time frame: From baseline (treatment) up to week 24.
Number of Laser Treatments
Total number of laser treatment in both eyes. If multiple sessions of laser treatment were necessary within 1 week from baseline, they were counted as a single treatment.
Time frame: From baseline (treatment) up to week 24.
Study was conducted at 64 centers in 27 countries or regions, between 25-SEP-2019 (first participant first visit) and 12-Feb-2021 (last participant last visit).
| Milestone | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Started | 75 | 38 |
| Saf | 75 | 38 |
| Pks | 75 | 0 |
| Aas | 75 | 0 |
| Completed | 68 | 36 |
| Not completed | 7 | 2 |
| Withdrew: Withdrawal by parent/guardian | 1 | 1 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Covid-19 pandemic | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
Active ROP was defined as ROP requiring treatment. Unfavorable structural outcomes included retinal detachment, macular dragging, macular fold, or retrolental opacity.
| Proportion of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes | 0.855 | 0.821 |
A second treatment modality for ROP was either rescue treatment or any other surgical or nonsurgical treatment for ROP (e.g. IVT anti-VEGF injection, ablative laser therapy, cryotherapy, or vitrectomy) captured as concomitant medication or surgery after study start.
| Proportion of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Proportion of Participants Requiring Intervention With a Second Treatment Modality | 0.072 | 0.096 |
Participants with recurrence of ROP were defined as subjects requiring re-treatment or rescue treatment after in the past the absence of treatment-requiring active ROP had been confirmed by the investigator.
| Proportion of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Proportion of Participants With Recurrence of ROP | 0.161 | 0.063 |
Eyes were evaluated for change in ROP activity scale proposed by the International Neonatal Consortium (2018). ROP Activity Scale value range is from 0 to 22. Value 0 to 7 are considered mild, 8 to 12 are moderate, and 13 to 22 are severe. Value 0 means the best and value 22 means the worst. Eyes evaluation was done at baseline and each visit.
| Scores on a scale | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Baseline | 16.20 ± 2.81 | 15.63 ± 3.53 |
| Change from baseline to Week 24 | -15.42 ± 4.46 | -14.77 ± 4.19 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular TEAEs in treated eyes only were reported
| Percentage of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) | 38.7 | 36.8 |
Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular SAEs in treated eyes only were reported.
| Percentage of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With Ocular Serious Adverse Events (SAEs) | 13.3 | 7.9 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic TEAEs only were reported.
| Percentage of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With Systemic TEAEs | 52.0 | 63.2 |
Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic SAEs only were reported.
| Percentage of participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Percentage of Participants With Systemic SAEs | 24.0 | 36.8 |
Blood samples for determination of aflibercept concentrations in plasma were collected in the aflibercept 0.4 mg arm at Day 1 (within 24 hours after injection), and at weeks 2 and 4, and if feasible also at weeks 8, 12 and 24. Statistics for week 8, 12, 24 not calculated as \> 1/3 of the concentrations were below the lower limit of quantification. Free Aflibercept Concentrations in Plasma were only measured in the Aflibercept 0.4 mg treatment arm.
| ng/mL | Aflibercept 0.4 mg |
|---|---|
| WEEK 0, DAY 1 | 480.607 ± 884.724 |
| WEEK 2 | 218.965 ± 358.933 |
| WEEK 4 | 133.093 ± 205.052 |
Immunogenicity was characterized by anti-drug antibody (ADA) responses in patients in the aflibercept 0.4 mg arm. Serum samples were taken at baseline prior to the injection and at 12 weeks after injection. ADA titers were summarized for 3 categories: Low (titer \<1,000); Moderate (1,000 ≤ titer ≤ 10,000); High (titer \>10,000). ADA in serum were only measured in the Aflibercept 0.4 mg treatment arm.
| Participants | Aflibercept 0.4 mg |
|---|---|
| Baseline — ADA positive response | 0 |
| Baseline — ADA negative response | 75 |
| Week 12 — ADA positive response | 1 |
| Week 12 — ADA negative response | 74 |
NAb status was evaluated for the samples that were positive in the ADA assay and had sufficient volume to analyze. NAb were only measured in participants with positive ADA in the Aflibercept 0.4 mg treatment arm
| Participants | Aflibercept 0.4 mg |
|---|---|
| Number of Participants With Potential Neutralizing Antibodies (NAb) | 0 |
Total number of injections in both eyes.
| Participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| 0 aflibercept administration | 0 | 34 |
| 1 aflibercept administration | 4 | 0 |
| 2 aflibercept administrations | 55 | 3 |
| 3 aflibercept administrations | 6 | 1 |
| 4 aflibercept administrations | 10 | 0 |
Total number of laser treatment in both eyes. If multiple sessions of laser treatment were necessary within 1 week from baseline, they were counted as a single treatment.
| Participants | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| 0 laser treatment | 70 | 0 |
| 1 laser treatment | 3 | 4 |
| 2 laser treatments | 2 | 30 |
| 3 laser treatments | 0 | 1 |
| 4 laser treatments | 0 | 2 |
| 6 laser treatments | 0 | 1 |
Collected over After the first administration and not later than 30 days after the last administration of study treatment, up to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 0.4 mg | 3/75 (4%) | 9/75 (12%) | 53/75 (70.7%) |
| Laser Photocoagulation | 0/38 (0%) | 10/38 (26.3%) | 23/38 (60.5%) |
| Event | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Retinal detachmentEye disorders | 3/75 | 2/38 |
| Infantile apnoeaRespiratory, thoracic and mediastinal disorders | 0/75 | 2/38 |
| Retinal haemorrhageEye disorders | 2/75 | 0/38 |
| BronchiolitisInfections and infestations | 2/75 | 1/38 |
| Pulmonary valve stenosisCardiac disorders | 0/75 | 1/38 |
| Necrotising colitisGastrointestinal disorders | 0/75 | 1/38 |
| ConjunctivitisInfections and infestations | 0/75 | 1/38 |
| RhinitisInfections and infestations | 0/75 | 1/38 |
| C-reactive protein increasedInvestigations | 0/75 | 1/38 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/75 | 1/38 |
| Event | Aflibercept 0.4 mg | Laser Photocoagulation |
|---|---|---|
| Retinal haemorrhageEye disorders | 4/75 | 5/38 |
| Eyelid oedemaEye disorders | 2/75 | 3/38 |
| Umbilical herniaGastrointestinal disorders | 1/75 | 3/38 |
| ConjunctivitisInfections and infestations | 3/75 | 3/38 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 0/75 | 3/38 |
| Conjunctival haemorrhageEye disorders | 4/75 | 0/38 |
| AnaemiaBlood and lymphatic system disorders | 1/75 | 2/38 |
| Anaemia neonatalBlood and lymphatic system disorders | 0/75 | 2/38 |
| Bacterial disease carrierInfections and infestations | 0/75 | 2/38 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 2/75 | 2/38 |
SAF
| Age, Continuous(weeks) | Aflibercept 0.4 mg | Laser Photocoagulation | Total |
|---|---|---|---|
| Mean | 26.43 ± 2.1 | 26 ± 1.6 | 26.29 ± 1.9 |
| Age, Customized(Participants) | Aflibercept 0.4 mg | Laser Photocoagulation | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 75 | 38 | 113 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Aflibercept 0.4 mg | Laser Photocoagulation | Total |
|---|---|---|---|
| Female | 34 | 19 | 53 |
| Male | 41 | 19 | 60 |
| Race/Ethnicity, Customized(Participants) | Aflibercept 0.4 mg | Laser Photocoagulation | Total |
|---|---|---|---|
| White | 55 | 28 | 83 |
| Black or African American | 2 | 0 | 2 |
| Asian Indian | 0 | 2 | 2 |
| Chinese | 4 | 0 | 4 |
| Japanese | 10 | 6 | 16 |
| Korean | 2 | 1 | 3 |
| Asian: Other | 1 | 0 | 1 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Multiple | 1 | 0 | 1 |
| ROP classification by investigator(Participants) | Aflibercept 0.4 mg | Laser Photocoagulation | Total |
|---|---|---|---|
| Zone I excluding AP-ROP | 15 | 7 | 22 |
| Zone II excluding AP-ROP | 46 | 26 | 72 |
| AP-ROP: Zone I | 12 | 4 | 16 |
| AP-ROP: Zone II | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Sep 2019 to primary completion in Feb 2021, 16 months.
Results were first posted in May 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept